Meta-Analysis Characterizes Benefits, Risks of Novel Nonsteroidal MRAs
Investigators examined the efficacy and hyperkalemia risk of the nonsteroidal MRAs finerenone, apararenone, and esaxerenone.
Source: renalandurologynews.com
Stay updated with breaking news from Xiaofeng Pu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investigators examined the efficacy and hyperkalemia risk of the nonsteroidal MRAs finerenone, apararenone, and esaxerenone.